H.Res. 532, introduced in the 119th Congress, designates Brain and Spine Metastasis Awareness Month and expresses House support for heightened education and awareness about treatment options for cancers that spread to the brain or spine. It also directs the Secretary of Health and Human Services to take concrete steps—expand education on available therapies (including targeted therapies and immunotherapies), establish and support dedicated centers, improve access to brain- and spine-metastasis clinical trials, and invest in research focused on the biology and treatment of metastases across cancers.
The resolution is non-binding; it sets priorities and signals federal attention but does not itself authorize new funding or create enforceable obligations.
At a Glance
What It Does
The resolution endorses designating Brain and Spine Metastasis Awareness Month and directs HHS to pursue four actions: broaden education on metastasis treatment options, establish and support specialized centers, increase access to clinical trials, and invest in relevant research.
Who It Affects
Directly affects patients with cancers that metastasize to the brain or spine, their families, oncology clinics and trial networks, cancer research centers, and federal public health agencies.
Why It Matters
Brain and spine metastases are a leading cause of morbidity in cancer patients and are increasingly common as treatments extend survival. Awareness and access to targeted therapies, trials, and specialized centers can materially affect outcomes and quality of life.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
This resolution signals Congress’s intent to raise the profile of brain and spine metastasis as a critical cancer issue. It does not itself change law or funding but aligns House priorities around four concrete avenues for action by the executive branch.
First, it asks the Secretary to boost education and information about current treatment options, including newer therapies. Second, it calls for the creation and support of centers specialized in brain and spine metastasis to improve care coordination.
Third, it urges resources be directed to expand access to clinical trials for patients facing brain or spine metastases. Finally, it directs investment in research to better understand the biology of metastasis and to develop therapies that cross cancer types.
The overall intent is to translate medical advances into accessible care pathways and to reduce barriers for patients and families navigating metastatic disease. In essence, the resolution designates an awareness month and sharpens federal focus on education, access, and research without prescribing funding or mandating new programs.
The Five Things You Need to Know
The resolution designates Brain and Spine Metastasis Awareness Month (non-binding).
It urges the Secretary to expand patient education on treatment options, including targeted therapies and immunotherapies.
It calls for resources to establish and support dedicated brain/spine metastasis centers.
It seeks to increase access to brain/spine metastasis clinical trials for patients.
It directs investment in cross-cancer research on the biology and treatment of brain and spine metastases.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation and recognition of Brain and Spine Metastasis Awareness Month
This section articulates House support for branding a dedicated awareness month. The emphasis is on raising attention among patients, families, clinicians, and researchers, setting the tone for subsequent actions without creating new legal mandates.
Education and awareness of treatment options
The resolution instructs the Secretary to expand public and professional education about available treatments, including advances like targeted therapies and immunotherapies. The aim is to improve understanding among patients and clinicians, reduce information gaps, and support informed decision-making during care planning.
Centers and access to clinical trials
This provision calls for establishing or supporting centers specialized in brain and spine metastasis and for resources to expand patient access to dedicated clinical trials. The intent is to improve multidisciplinary care and accelerate trial enrollment for patients with central nervous system metastases.
Research investment across cancers
The final provision directs investment in research focused on the biology and treatment of brain and spine metastases, with emphasis on cross-cancer insights. The goal is to foster new therapies and a deeper scientific understanding that can generalize across tumor types.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with brain or spine metastases and their families, who gain access to better information and potential treatment options
- Specialized brain/spine metastasis centers and multidisciplinary clinics that improve patient care pathways
- Neuro-oncology researchers and academic medical centers pursuing cross-cancer insights into metastasis
- Clinical-trial networks and patient advocacy organizations seeking broader trial access and engagement
- Healthcare providers coordinating metastatic care
Who Bears the Cost
- No new statutory funding is authorized by this resolution, but implementing the actions could incur administrative costs for HHS and related agencies
- HHS components may need to allocate staff time and resources to develop and disseminate educational materials and to coordinate center networks
- Public health outreach, clinical trial facilitation, and research coordination could require reallocation of existing budgets or cross-agency collaboration
- Hospitals and centers participating in new or expanded metastasis-focused programs may incur transitional or setup costs as they align with federal guidance and centers’ missions
Key Issues
The Core Tension
The central tension is between symbolic political support for awareness and the concrete resource commitments required to realize meaningful improvements in education, centers, trials access, and research. Without explicit appropriations, the resolution relies on existing budgets and interagency collaboration, which may slow or limit the scope of its impact.
As a resolution, H.Res. 532 does not authorize new federal programs or appropriations. Its value lies in directing attention and signaling priorities.
The practical impact depends on how HHS and related agencies translate the four requested actions into funded programs or partnerships, which are not guaranteed by the text. There could be uneven implementation across states and institutions, given that any expansion of education, center networks, trials access, or cross-cancer research requires resources and coordination.
Stakeholders should watch for where federal funding and interagency agreements, if any, materialize to support these efforts.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.